Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules
NCT04047186 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2025-09-23
Summary
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study
Conditions
- Multiple Pulmonary Nodules
Interventions
- DRUG
-
Tislelizumab Injection
Patients in the experimental group receive Tislelizumab Injection
Sponsors & Collaborators
-
XiangNing Fu
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-01
- Primary Completion
- 2024-12-31
- Completion
- 2025-05-30
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
NCT07109401 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
NCT03594747 ·Status: COMPLETED ·Phase: PHASE3
-
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients
NCT06496009 ·Status: NOT_YET_RECRUITING
-
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
NCT06356675 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
NCT05024266 ·Status: UNKNOWN ·Phase: PHASE2
-
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
NCT05207904 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
NCT06607926 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
NCT05940532 ·Status: RECRUITING ·Phase: PHASE2
-
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
NCT05319574 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
NCT04612673 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type
NCT05023837 ·Status: COMPLETED
-
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
NCT03663205 ·Status: COMPLETED ·Phase: PHASE3
-
SinTilimab After Radiation (STAR Study)
NCT04167657 ·Status: COMPLETED ·Phase: PHASE2
-
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
NCT07085182 ·Status: RECRUITING ·Phase: PHASE2
-
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
NCT05758116 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
NCT03659578 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT07103395 ·Status: RECRUITING ·Phase: PHASE2
-
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
NCT06357598 ·Status: RECRUITING ·Phase: PHASE4
-
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
NCT04405674 ·Status: UNKNOWN ·Phase: PHASE2
-
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NCT06883552 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
NCT05611879 ·Status: RECRUITING ·Phase: PHASE2
-
Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer
NCT06962449 ·Status: ENROLLING_BY_INVITATION
-
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT07086456 ·Status: RECRUITING ·Phase: PHASE2
-
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
NCT03007875 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
NCT03944980 ·Status: UNKNOWN ·Phase: PHASE3